A study detailing the results of a clinical trial carried out by Robert Hindes, MD, in collaboration with other researchers explores the potency of daclatasvir, a NS5A replication complex inhibitor, when combined with peginterferon and ribavirin in the treatment of chronic hepatitis C (HCV). The study appeared in September 2012’s The Lancet Infectious Diseases Journal. Individuals can read the abstract for the paper, which appeared as “Daclatasvir for Previously Untreated Chronic Hepatitis C Genotype-1 Infection: a Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Trial,” online at www.thelancet.com.
The study’s findings demonstrate that daclatasvir, in combination with peginterferon and ribavirin, is safe and effective at all doses studied. The authors conclude that continued development of treatment regimens that utilize 60 milligrams of daclatasvir is supported by study results.
Recent research on HCV also co-published by Dr. Hindes includes “Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C” in the New England Journal of Medicine.